BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Organetix, Inc. (DMND) Announces Raw Material Availability To Treat Up To 5,000 Patients Per Month


10/19/2005 5:10:07 PM

NEW YORK--(BUSINESS WIRE)--Feb. 23, 2004--Organetix, Inc. (www.organetixinc.com) (OTC BB: OGTX) confirms that there currently exists sufficient raw material availability to produce enough of our A4+L Liver Product to treat up to 5,000 patients per month.

Brad Clarke, President and CEO of Organetix stated, "The desire to procure large quantities of our liver product's vital ingredients demonstrates our capability to begin to support the future demand for our Liver Product."

About Organetix, Inc.

Organetix is a biotechnology company that has the exclusive worldwide license for the formula of a proprietary medical discovery relating to the liver. This liver product has been used specifically to treat patients with Hepatitis C. Limited research shows it is regenerating liver tissue thus allowing the liver to begin functioning again despite years of damage from the virus. Therefore, this product may be useful for treating all liver disorders including cirrhosis and may someday eliminate most liver transplants. Much like insulin being used for diabetes, this proprietary liver product does not cure Hepatitis C but has the capability of regenerating the liver.

Management, together with research and medical advisors are reporting that the formula, in the limited tests conducted to date eliminates most of the symptoms of Hepatitis C quickly and effectively without any known side effects. The liver product will directly compete in a billion dollar market that currently exists around the world.

Organetix will specialize in researching, developing and patenting bioactive compounds and their unique formulas and processes from plants having a unique history of medicinal use. We feel that Nutraceuticals and Bioceuticals are the foundations for the new and exciting drugs to be discovered in the 21st Century.

Statements contained in this press release, which are not historical facts, are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties beyond the Company's control, including but not limited to economic, competitive and other factors affecting the Company's operations, management team effectiveness, expansion strategies, available financing, market prices and recovery costs, government regulations involving the Company, facts and events not known at the time of this release, and other factors discussed in the Company's filings with the Securities and Exchange Commission.

These statements are not guarantees of future performance and readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update publicly any forward-looking statements.

Contacts

Corporate Communications Group, Inc. David Pomerantz, 516-791-0000 ext. 102



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES